Ozden Seyma, Gokdemir Isil, Kiyik Murat
Department of Immunology and Allergy, University of Health Sciences, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkiye.
Intensive Care Unit, Karabuk Training and Research Hospital, Karabuk, Turkiye.
North Clin Istanb. 2024 Sep 12;11(5):367-372. doi: 10.14744/nci.2023.25349. eCollection 2024.
The aim of this study was to evaluate the relationship between the degree of visceral pleural invasion (VPI) and survival in patients operated for non-small cell lung cancer (NSCLC).
Between 2013 and 2015, 202 patients who were diagnosed with NSCLC in our center and followed up in our clinic were retrospectively evaluated. To examine the preoperative and postoperative prognostic factors of the patients, postoperative pathology results, demographic data and data on recurrence status were obtained from our hospital database and patient files.
VPI Survival analysis was performed by dividing 3 groups: PL0, PL1 and PL2. Mean survival (MS) was calculated as 39.528±1.469 (36.655-42.402; 95% CI) months for PL0, 35.136±3.115 (29.031-41.240; 95% CI) months for PL1, and 24.688±3.697 (17.441-31.934; 95% CI) for PL2 (p=0.020). When we consider PL0 and PL1 as a single group and compare it with PL2, the MS time of the PL0-PL1 group was 38.358±1.346 (35.721-40.995; 95% CI) months, while the MS time of the PL2 group was 24.688±3.697 (17.441-31.934; 95% CI) months (p=0.020).
Although PL0, PL1 and PL2 were classified into a single group (all considered as T2), this study showed that the presence of PL2 was associated with a poor prognosis in terms of survival, independent of lymph node involvement, histopathological subtype of the tumor and tumor size.
本研究旨在评估非小细胞肺癌(NSCLC)手术患者的脏层胸膜侵犯(VPI)程度与生存率之间的关系。
回顾性评估2013年至2015年期间在本中心诊断为NSCLC并在本诊所进行随访的202例患者。为检查患者的术前和术后预后因素,从我院数据库和患者病历中获取术后病理结果、人口统计学数据和复发状态数据。
通过将患者分为3组进行VPI生存分析:PL0、PL1和PL2。PL0组的平均生存时间(MS)计算为39.528±1.469(36.655 - 42.402;95%可信区间)个月,PL1组为35.136±3.115(29.031 - 41.240;95%可信区间)个月,PL2组为24.688±3.697(17.441 - 31.934;95%可信区间)(p = 0.020)。当我们将PL0和PL1视为一个单一组并与PL2进行比较时,PL0 - PL1组的MS时间为38.358±1.346(35.721 - 40.995;95%可信区间)个月,而PL2组的MS时间为24.688±3.697(17.441 - 31.934;95%可信区间)个月(p = 0.020)。
尽管PL0、PL1和PL2被归类为一个单一组(均视为T2),但本研究表明,PL2的存在与生存率方面的不良预后相关,与淋巴结受累、肿瘤的组织病理学亚型和肿瘤大小无关。